NewG Lab Acquires Arije Yak... "Boosting Development of Anticancer New Drugs"

[Asia Economy Reporter Hyunseok Yoo] NewG Lab announced on the 25th that it has acquired the management rights of Arije Yak, a domestic pharmaceutical manufacturing company.

With this acquisition, NewG Lab has secured a GMP facility for direct production of new drugs, absorbed 87 product licenses and a pharmaceutical research organization, thereby significantly expanding its research and development (R&D) capabilities. Additionally, it has established a comprehensive pharmaceutical company system by securing the value chain for the entire bio business process, including new drug R&D, production, regulatory approval, marketing, and pharmaceutical transportation (cold chain).

Arije Yak obtained the Korea Good Manufacturing Practice (KGMP) certification from the Ministry of Food and Drug Safety (MFDS) in 2019 and has secured product licenses for a total of 87 pharmaceuticals as of last year, making it a pharmaceutical company with promising growth potential.

Through this acquisition, NewG Lab has secured a stable production base for its self-developed new drugs. NewG Lab is preparing for FDA clinical trials for its next-generation metabolic anticancer drug KAT (Ko Anticancer Technology). It has signed CMO and CDMO contracts with global pharmaceutical companies such as Merck in Germany and AMRI in the UK, and based on the know-how gained through these processes, it plans to establish an independent production system for KAT.

In addition to KAT, NewG Lab plans to directly produce Taletrectinib, a non-small cell lung cancer treatment drug that has already completed Phase 1 and is preparing for global Phase 2 clinical trials. Recently, the Ministry of Health and Welfare named NewGen Napamo Tablets, an oral COVID-19 treatment expected to be launched within the year, as one of the promising candidates. With the acquisition of Arije Yak, NewG Lab will also be able to directly produce NewGen Napamo Tablets.

Furthermore, NewG Lab plans to design and launch various new products, including combination drugs, which are expected to see increased market demand in the future.

A NewG Lab official stated, “By acquiring Arije Yak, we have secured essential production facilities, enabling us to independently handle everything from new drug R&D to production, distribution, and bio cold chain. We will grow into a comprehensive pharmaceutical company through the development and commercialization of various new drugs.”

Chosungsoo, CEO of Arije Yak, emphasized, “With the excellent research personnel from NewG Lab, which is developing global new drugs, joining us, we expect to maximize Arije Yak’s R&D capabilities. Through synergy between the two companies, Arije Yak will also be able to increase sales and secure a stable market position.” He added, “Arije Yak will expand facilities that meet global standards to serve as NewG Lab’s new drug production base.”